SUPERNUS PHARMACEUTICALS INC (SUPN) Fundamental Analysis & Valuation

NASDAQ:SUPN • US8684591089

Current stock price

49.38 USD
+0.13 (+0.26%)
At close:
49.38 USD
0 (0%)
After Hours:

This SUPN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. SUPN Profitability Analysis

1.1 Basic Checks

  • SUPN had positive earnings in the past year.
  • SUPN had a positive operating cash flow in the past year.
  • SUPN had positive earnings in 4 of the past 5 years.
  • In the past 5 years SUPN always reported a positive cash flow from operatings.
SUPN Yearly Net Income VS EBIT VS OCF VS FCFSUPN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M 100M 150M

1.2 Ratios

  • SUPN has a Return On Assets of -2.65%. This is in the better half of the industry: SUPN outperforms 75.65% of its industry peers.
  • SUPN has a Return On Equity of -3.63%. This is in the better half of the industry: SUPN outperforms 78.24% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 0.76%, SUPN is in the better half of the industry, outperforming 78.24% of the companies in the same industry.
  • SUPN had an Average Return On Invested Capital over the past 3 years of 2.78%. This is significantly below the industry average of 13.06%.
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROIC 0.76%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
SUPN Yearly ROA, ROE, ROICSUPN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

1.3 Margins

  • SUPN has a Operating Margin of 1.55%. This is in the better half of the industry: SUPN outperforms 78.24% of its industry peers.
  • In the last couple of years the Operating Margin of SUPN has declined.
  • SUPN's Gross Margin of 89.89% is amongst the best of the industry. SUPN outperforms 92.75% of its industry peers.
  • In the last couple of years the Gross Margin of SUPN has remained more or less at the same level.
Industry RankSector Rank
OM 1.55%
PM (TTM) N/A
GM 89.89%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
SUPN Yearly Profit, Operating, Gross MarginsSUPN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. SUPN Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
  • Compared to 1 year ago, SUPN has more shares outstanding
  • SUPN has more shares outstanding than it did 5 years ago.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SUPN Yearly Shares OutstandingSUPN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
SUPN Yearly Total Debt VS Total AssetsSUPN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • SUPN has an Altman-Z score of 5.62. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of SUPN (5.62) is better than 79.27% of its industry peers.
  • SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 5.62
ROIC/WACC0.08
WACC9.45%
SUPN Yearly LT Debt VS Equity VS FCFSUPN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.3 Liquidity

  • A Current Ratio of 1.90 indicates that SUPN should not have too much problems paying its short term obligations.
  • The Current ratio of SUPN (1.90) is worse than 61.66% of its industry peers.
  • SUPN has a Quick Ratio of 1.66. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
  • SUPN's Quick ratio of 1.66 is in line compared to the rest of the industry. SUPN outperforms 40.41% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.66
SUPN Yearly Current Assets VS Current LiabilitesSUPN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. SUPN Growth Analysis

3.1 Past

  • SUPN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 8.14%, which is quite good.
  • Measured over the past 5 years, SUPN shows a small growth in Earnings Per Share. The EPS has been growing by 6.21% on average per year.
  • Looking at the last year, SUPN shows a quite strong growth in Revenue. The Revenue has grown by 8.63% in the last year.
  • SUPN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 6.68% yearly.
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%

3.2 Future

  • The Earnings Per Share is expected to grow by 17.52% on average over the next years. This is quite good.
  • SUPN is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 14.29% yearly.
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
SUPN Yearly Revenue VS EstimatesSUPN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
SUPN Yearly EPS VS EstimatesSUPN Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 2 4 6 8 10

More info and screens

Find the best growth stocksShow best growing peers

4

4. SUPN Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 15.48, the valuation of SUPN can be described as correct.
  • 86.01% of the companies in the same industry are more expensive than SUPN, based on the Price/Earnings ratio.
  • SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 25.50, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 25.17, SUPN can be considered very expensive at the moment.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 75.13% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.67, SUPN is valued at the same level.
Industry RankSector Rank
PE 15.48
Fwd PE 25.17
SUPN Price Earnings VS Forward Price EarningsSUPN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, SUPN is valued a bit cheaper than the industry average as 79.79% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, SUPN is valued a bit cheaper than the industry average as 75.65% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 61.82
EV/EBITDA 22.84
SUPN Per share dataSUPN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • A more expensive valuation may be justified as SUPN's earnings are expected to grow with 18.42% in the coming years.
PEG (NY)N/A
PEG (5Y)2.49
EPS Next 2Y23.69%
EPS Next 3Y18.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. SUPN Dividend Analysis

5.1 Amount

  • No dividends for SUPN!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

SUPN Fundamentals: All Metrics, Ratios and Statistics

SUPERNUS PHARMACEUTICALS INC

NASDAQ:SUPN (3/24/2026, 8:02:55 PM)

After market: 49.38 0 (0%)

49.38

+0.13 (+0.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-24
Earnings (Next)05-04
Inst Owners103.58%
Inst Owner Change-0.71%
Ins Owners4.32%
Ins Owner Change2.61%
Market Cap2.84B
Revenue(TTM)718.95M
Net Income(TTM)-38.55M
Analysts83.33
Price Target62.56 (26.69%)
Short Float %7.45%
Short Ratio5.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)105.02%
Min EPS beat(2)67.83%
Max EPS beat(2)142.22%
EPS beat(4)4
Avg EPS beat(4)78.33%
Min EPS beat(4)15.55%
Max EPS beat(4)142.22%
EPS beat(8)7
Avg EPS beat(8)76.31%
EPS beat(12)10
Avg EPS beat(12)66.61%
EPS beat(16)11
Avg EPS beat(16)43.29%
Revenue beat(2)2
Avg Revenue beat(2)5.83%
Min Revenue beat(2)5.28%
Max Revenue beat(2)6.37%
Revenue beat(4)3
Avg Revenue beat(4)4.06%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)6.37%
Revenue beat(8)6
Avg Revenue beat(8)5.39%
Revenue beat(12)9
Avg Revenue beat(12)4.44%
Revenue beat(16)11
Avg Revenue beat(16)2.87%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-35.15%
EPS NQ rev (3m)11.24%
EPS NY rev (1m)-46.67%
EPS NY rev (3m)-54.71%
Revenue NQ rev (1m)-0.66%
Revenue NQ rev (3m)0.41%
Revenue NY rev (1m)0.88%
Revenue NY rev (3m)-0.23%
Valuation
Industry RankSector Rank
PE 15.48
Fwd PE 25.17
P/S 3.95
P/FCF 61.82
P/OCF 60.07
P/B 2.68
P/tB 7.74
EV/EBITDA 22.84
EPS(TTM)3.19
EY6.46%
EPS(NY)1.96
Fwd EY3.97%
FCF(TTM)0.8
FCFY1.62%
OCF(TTM)0.82
OCFY1.66%
SpS12.49
BVpS18.44
TBVpS6.38
PEG (NY)N/A
PEG (5Y)2.49
Graham Number36.38
Profitability
Industry RankSector Rank
ROA -2.65%
ROE -3.63%
ROCE 1%
ROIC 0.76%
ROICexc 1.05%
ROICexgc 7.57%
OM 1.55%
PM (TTM) N/A
GM 89.89%
FCFM 6.4%
ROA(3y)0.95%
ROA(5y)1.92%
ROE(3y)1.21%
ROE(5y)3.41%
ROIC(3y)2.78%
ROIC(5y)3.35%
ROICexc(3y)4.57%
ROICexc(5y)5.05%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.69%
ROCE(5y)4.7%
ROICexgc growth 3Y-30.81%
ROICexgc growth 5Y-24.6%
ROICexc growth 3Y-31.42%
ROICexc growth 5Y-41%
OM growth 3Y-36.8%
OM growth 5Y-45.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.12%
GM growth 5Y0%
F-Score5
Asset Turnover0.49
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1.46%
Cap/Sales 0.19%
Interest Coverage 250
Cash Conversion 46.07%
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.66
Altman-Z 5.62
F-Score5
WACC9.45%
ROIC/WACC0.08
Cap/Depr(3y)1%
Cap/Depr(5y)1.92%
Cap/Sales(3y)0.13%
Cap/Sales(5y)0.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.14%
EPS 3Y45.76%
EPS 5Y6.21%
EPS Q2Q%12%
EPS Next Y-38.5%
EPS Next 2Y23.69%
EPS Next 3Y18.42%
EPS Next 5Y17.52%
Revenue 1Y (TTM)8.63%
Revenue growth 3Y2.52%
Revenue growth 5Y6.68%
Sales Q2Q%21.48%
Revenue Next Year23.16%
Revenue Next 2Y20.6%
Revenue Next 3Y18.26%
Revenue Next 5Y14.29%
EBIT growth 1Y-87.66%
EBIT growth 3Y-35.2%
EBIT growth 5Y-41.44%
EBIT Next Year14.86%
EBIT Next 3Y40.14%
EBIT Next 5Y27.81%
FCF growth 1Y-73.14%
FCF growth 3Y-26.62%
FCF growth 5Y-19.37%
OCF growth 1Y-72.47%
OCF growth 3Y-26%
OCF growth 5Y-19.31%

SUPERNUS PHARMACEUTICALS INC / SUPN Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 5 / 10 to SUPN.


What is the valuation status for SUPN stock?

ChartMill assigns a valuation rating of 4 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.


What is the profitability of SUPN stock?

SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.


Can you provide the expected EPS growth for SUPN stock?

The Earnings per Share (EPS) of SUPERNUS PHARMACEUTICALS INC (SUPN) is expected to decline by -38.5% in the next year.